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1. INTRODUCTION 
1.1 Cancer    
Cancer is with increasing significance a major global health problem, and it represents a 
group of diseases which are most importantly characterized by abnormal cell growth with the 
potential to invade and or metastasize to other sides in the human body. This distinguishes cancers 
from benign tumors, which cannot spread across the side of its origin. However, several research 
studies suggest that cancers are monoclonal in their origin, implying that the malignant 
transformation started in one single cell. The cellular process of developing cancer cells is a 
complex and long-lasting one, which requires several stages to turn healthy tissue into cancer. This 
process is called tumor progression (1). 
According to the newest model of ”The Hallmarks of Cancer” by Douglas Hanahan and 
Robert Weinberg, all known cancers have ten traits in common which enable them to modulate 
themselves from a normal to a cancerous cell, presented in the following list: 
1. Self-sufficient in growth signals; 
2. Insensitive to inhibitory anti-growth signals; 
3. Resistant to apoptosis; 
4. Limitless replication potential; 
5. Stimulate angiogenesis; 
6. Invade surrounding tissues and metastasize; 
7. Disturbed metabolic pathways; 
8. Evade the immune system; 
9. Genomic instability; 
10. Inflammation (2). 
 The differences in etiology, pathology, and clinical presentation of cancers lead to various 
therapeutic angles, but unfortunately, it mostly results in the lack of a sufficient and standardized 
treatment regime (1,2).  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1.2 Triple-negative breast cancer 
1.2.1 Definition of TNBC 
 The term triple-negative breast cancer was first introduced in 2005, and is generally 
abbreviated as TNBC. Overall it refers to a genomically heterogenic group of breast cancers which 
make up 12-17% of all breast cancers and are defined by their unifying lack of expression of 
estrogen receptor (ER) and progesterone receptor (PR), and the absence of human epidermal growth 
factor receptor 2 amplification (HER2) (3,4). Furthermore, it has to be emphasized that TNBC is 
not a synonym for basal-like cancer. Basal-like breast cancers are often used as a surrogate term for 
triple-negative breast cancers even though only 80% of basal-like breast cancers are truly triple-
negative in their receptor expression. 10% are ER+/HER2- and 2% are even HER2+ (5). 
1.2.2 Epidemiology and etiology 
 Breast cancer is a prevalent and significant disease in females with several potentially severe 
adverse effects on a woman’s life. The importance of this cancer stressed by the fact that in 2018, 
breast cancer was the most common type of cancer in females in 154 countries worldwide, 
according to the World Health Organization (WHO), accounting for 2.08 million new cases in 
women (Table 1). Furthermore, breast cancer is not only the most commonly diagnosed female 
cancer type in the world, constituting for 24.2% out of 8.6 million cases of all newly diagnosed 
female cancer patients, but also together with lung cancer, it is the most frequently diagnosed cancer 
in general, as shown in Figure 1 A and B. The incidence of breast cancer cases in 2018, for males 
and females together, is 11.6% out of 18.1 million new cancer cases, same as for lung cancer, but 
99.12% of the new breast cancer cases are in females, highlighting the immense female 
predominance of this cancer (Figure 1B, Table 1). Concerning cancer mortality, breast cancer is one 
of the leading causes of cancer-related deaths. In 2018, breast cancer accounted for 0.6336 million 
deaths. 99.43% of these were women, making it the 5th most lethal cancer in the world (Table 1). 
Lung cancer is in the general population the leading cause of cancer-related deaths in humans being 
responsible for 18.4% out of 9.6 million deaths, but breast cancer constitutes to the highest female 
cancer mortality with 15% out of 4.2 million deaths and is, therefore, the principal cause of cancer-
related deaths in women in at least 103 countries according to the WHO (Figure 1, Table 1) (6). 
  
"3
Figure 1. Pie charts depicting for the ten most common cancers the distribution of new cases and 
deaths in 2018 for (A) females and (B) both sexes. The area of the pie chart represents the 
proportion of the total number of new cases or deaths; the category ”others” includes nonmelanoma 
skin cancers.  
SOURCE: Globocan 2018, World Health Organization (6).  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Table 1. Cancer and breast cancer incidence and mortality in 2018. 
The  table  above  shows for both sexes and females the amount of people newly diagnosed with 
cancer and breast cancer and the mortality of cancer and breast cancer in 2018, as well as the 
percentage.  
SOURCE: Globocan 2018, World Health Organization. 
 The incidence of TNBC among breast cancer depends on several factors like, for instance, 
sex, race, and age of the patient. Not only is breast cancer itself more common in females than in 
males but also the TNBC type occurs mainly in females with an incidence of 13% and 6% 
respectively. Taking into account the race of a patient it was noticed that for example, in the 
African-American population, the incidence is the highest one yet determined accounting for 35% 
of all breast cancers diagnoses of this group. To be more precise it is stated that it is most prominent 
among non-Hispanic black and Hispanic patients (23.7% and 14.8%) and in the Caucasian 
population it only makes up around 15% (7). The lowest occurrences so far measured are in Filipino 
patients (8.9%), albeit Filipino women are known to be at a heightened risk for HER2+ cancers 
(7,8). For all ethnic groups, it is deemed to be that younger patients are more prone to have TNBC, 
with notable distinctions between Caucasian and African-American patients. As seen in Figure 2, 
for patients younger than 30-years of age, the two racial groups start with a roughly similar overall 
incidence of TNBC. In Caucasian patients, the TNBC percentage is highest for the age group 
around 30 years, and then it continuously declines, while in African-American patients, there is no 
significant decrease until the patients are older than 60-years, but even a slight increase during their 
thirties. Nonetheless, the graph shown in Figure 2 points out that African-American women of all 
age groups are at any time during their life more predisposed to have TNBC compared to Caucasian 
patients (7).  
2018
Incidence of new 
cancer cases
Incidence of new  
breast cancer cases
Mortality  
of cancer
Mortality  
of breast cancer
Females 8.6 million 2.0812 million 4.2 million 0.63 million
Both sexes 18.1 million 2.0996 million 9.6 million 0.6336 million
Percentage of Females 47.5% 99.12 % 43.75 % 99.43%
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Figure 2. Percentage of TNBC based on patient age and race.  
TNBC: triple-negative breast cancer.  
SOURCE: Plasilova et al (7). 
 TNBC is of course also associated with genetic, pathologic variants (PV), which underline 
how important it is to consider the race of a patient as the incidence of the different PVs varies 
immensely depending on whether a patient is of Caucasian ancestry or African-American. For 
example, an increased incidence in patients with germline BRCA1 mutations is commonly seen in 
Caucasians with TNBC, the most striking PVs with the highest incidence are BRCA1 and PALB2 
PVs which have a lifetime risk for TNBC of 18% and 10% respectively, followed by BARD1 with 
7%, 6% BRCA2, and 5% RAD51D, as shown in Figure 3A and B. Even though the same 
pathologic variants are found in African-American people, it has to be emphasized that the impact is 
far more drastic on their TNBC risk estimates for overall breast cancer, with 81% BRCA1, 62% 
BRCA2, 41% PALB2, and 39% BARD1 (Figure 3C and D) (9). Furthermore, around 70% of breast 
cancers diagnosed in people with an inherited BRCA mutation, particularly BRCA1, are classified 
as triple-negative (10). To summarize, one has to add that African-Americans have a large and 
diverse mutation profile with more genetic variants on numerous genes per patient, while 
Caucasians have PVs on fewer genes and also the deleterious PVs per patient are significantly less 
prevalent in Caucasians (11). 
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Figure 3. Absolute risk of specific pathologic variants for Caucasian (A and B) and African-
American (C and D) accessed to age 85 the overall breast cancer and triple-negative breast cancer 
risk. (A) Age-related risk curves for Caucasian overall breast cancer for six genes as color lines. (B) 
Age-related risk curves for Caucasian TNBC for six genes as colored dashed lines. (C) Age-related 
risk curves for African-American overall breast cancer for four genes as color lines. (D) Age-related 
risk curves for African-American TNBC for four genes as colored dashed lines.  
TNBC: triple-negative breast cancer.  
SOURCES: http://www.seer.cancer.gov and Shimelis et al (9). 
 Another apparent risk factor which is still under investigation is the oral contraceptive pill 
(OC). A study from 2009 compares the impact of taking OC on the risk of getting TNBC in women 
who took birth control pills for less than one year or never. The article states that taking OCs for at 
least one year causes a 2.5 times increase in risk for TNBC in females, and if the women are around 
the age 40 the increase is even 4.2 times. Furthermore, they also concluded that the prolonged 
duration of OC administration leads to an increased TNBC risk (12).  
"7
A B
C D
 However, in another study from 2011, which also covers the association of the patients’s 
reproductive history and their oral contraceptive usage in relation to the risk of getting TNBC, the 
increased risk of OCs for getting TNBC was not found. Albeit, it finds an association between 
nulliparity and the risk of breast cancer, showing a decreased incidence in TNBC patients but an 
increase in ER-positive ones (13). Another study from the same year strengthens the relevance of 
number of pregnancies in breast cancer patients, as it also states that the frequency of nulliparity is 
lowest in TNBC patients with 13% compared to other types of breast cancer, but it also says that 
multiparty, more precisely ≥3 kids is more common in TNBC (14,15). Aside from that, another 
known and relevant factor that decreases the risk of developing TNBC is breastfeeding for a 
prolonged duration or breastfeeding several children (15). 
 Besides, metabolic syndrome, characterized by obesity and insulin resistance, and a higher 
waist/hip ratio is also more prevalent in TNBC than it is in other breast cancers (15,16,17). Last but 
not least, another study found that alcoholism has a decreasing effect on the risk of getting TNBC 
and also concluded that smoking is not associated with TNBC (18). 
1.2.3 Pathophysiology 
 The formation of breast cancer development is, like in most other cancers, set off by a 
combination of multiple external environmental factors and their interaction in a genetically 
susceptible host (1). The CD44+/CD24- phenotype, which is known to be numerously common in 
cancer stem cells (CSC), represents the tumorigenic cells with stem cell-like properties, meaning 
the ability to extensively self-renew and give rise to phenotypically different cells with a decreased 
proliferative and developmental potential. The cell surface glycoprotein CD44 is crucial for the 
quick cancer progression as it plays a critical role in the adhesion, migration, and invasion of breast 
cancer cells (BCC), as well as in proliferation and metastasis (19,20). These CSC qualities do not 
only lead to the production of tumorigenic cells but also to the production of several phenotypically 
distinct nontumorigenic cells that make up the overall tumor mass. Due to the fact, that the only 
unifying characteristic of TNBC is the lack of the expression of ER, PR, and HER2, and due to the 
stem cell (SC) qualities of this cancer group, the creation of phenotypically heterogenic tumors is 
expected (4,21). The latest definition presented by the American Society of Clinical Oncology 
(ASCO) in their guidelines about the three main biomarkers ER, PR, HER2 states, that ER/PR is 
considered positive if ≥1% immunohistochemistry (IHC) and HER2 is considered positive if there 
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is protein expression of 3+, and/or HER2/neu gene amplification is ≥2.0 by fluorescence in situ 
hybridization (FISH). This means that the contemporary proper pathologic definition of TNBC 
actually is defined as 0% by IHC for ER and PR, and for HER2 negativity it states IHC expression 
of 0-1+ or lack of HER2/neu gene amplification (FISH <2.0) (22). 
 The most known genes responsible for breast cancer development are BRCA mutations and 
the germline mutations of the tumor protein 53 (p53) tumor suppressor gene (TSG). Even though 
BRCA mutations are only responsible for 5-10% of breast cancer cases in women, 70% of these are 
triple-negative, chiefly BRCA1 variants (10,23).  
 Besides, to the age of 80-years, these harmful mutations lead to an estimated cumulative risk 
of getting breast cancer of 72% and 69%, for BRCA1 and BRCA2 respectively (24). On top of this, 
the BRCA mutations form TSG complexes, where the BRCA1 modification combines with BARD1 
and causes the heterodimer BRCA1-BARD1, which interacts with RAD51 and the TSG complex 
BRCA2-PALB2. BRCA2 works together with PALB2, forming the TSG complex BRCA2-PALB2, 
PALB2 stands for partner and localizer of BRCA2, and both combined mutations have increased 
risks for breast cancer development and make targeted therapy even more difficult (25). Lastly, 
TP53 causes Li-Fraumeni syndrome and is, therefore, responsible for 4% of breast cancers among 
females under the age of 30-years (26). 
1.2.4 Clinical features and prognostics 
 Table 2 states the most important clinical and diagnostic factors concerning TNBC, but for 
further details, one can say that clinically, TNBC mostly presents as a palpable lump in the breast of 
younger females and is therefore usually not detected by the standard breast cancer screenings, 
which usually start around the age of 50. For women who attend regular screening programs, TNBC 
is known to typically present as an interval cancer, meaning between two mammographies. Withal, 
at the time of detection it commonly first manifests in a more unfavorable histopathologic 
condition, as it is often attended with lymphovascular invasion when it is diagnosed and the tumor 
is generally more massive in size, tends to present with clinically metastatic disease, and overall 
mostly in a higher cancer stage. Strictly speaking at the time of diagnosis, a striking majority of 
79.8% are grade III and the mean tumor size is 2.78 cm (Table 3). Only as little as 2.4% are grade I 
at the time of their first presentation. (7,27). Until in 2016, the newer study by Plasilova et al. was 
"9
published, it was believed that there is no correlation between increasing tumor size and lymph 
node involvement in TNBC, unlike in other breast cancer types, but as shown in Figure 4, positive 
lymph nodes are generally less common in TNBC, even though in bother BC groups the overall 
percentage of lymph node positivity is the same (7,28,29). Furthermore, it usually presents more 
aggressively and preferentially spreads hematogenously, leading to frequent visceral relapses in the 
brain and lungs (16).  
Table 2. Key points about TNBC characteristics. 
SOURCES: Plasilova et al (7); Kumar et al (27); Dent et al (28). 
 
 Speaking of visceral relapses, the pattern of recurrences shows a significant difference in 
TNBC compared to other BCs. First of all, distant metastases are more common than locoregional 
ones and also considerably more common in TNBC (33.9%) than in different subtypes (20.4%). 
After surgery, the relapse rate as shown in Figure 5, shows a striking increase in the first three years 
with the mean time to distant metastasis being 2.6 years compared to five years in other BCs, and 
interestingly the rate for distant metastases decreases quickly until it is rather uncommon eight years 
following the diagnosis. Furthermore, distal recurrences are rarely preceded by local ones, only in 
25% of women treated with breast-conserving surgery, which are only slightly more common in 
TNBC than in other types of breast cancers, but occur notedly sooner in TNBC after an estimated 
2.8 years versus 4.2 years respectively (27,28).  
Main characteristic features of TNBC phenotype:
Younger women (<50 years)
More frequent in African-American and black ethnicities
Presents as interval cancer
Less likely to have lymph node involvement
Steep increase in risk of recurrence after diagnosis
Peak risk of recurrence at 1-3 years
Distal recurrence more common than local ones; no distant relapse after 8 years
Higher mortality rate first 5 years; all deaths occur within 10 years of diagnosis
Short survival after distant recurrence
More aggressive with increase incidence of visceral metastasis (brain, lung)
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Table 3. Specific characteristic differences for TNBC compared to other types of breast cancers. 
*P values were calculated using the x2 test.  
SE=standard error; LVI, lymphovascular invasion.  
Full table shown in supplements (Table 2).  
SOURCE: Plasilova et al (7). 
Figure 4. Comparison of TNBC and non-TNBC regarding their tumor size and lymph node 
positivity in percentage (%).  
Abbreviations: TNBC, triple-negative breast cancer.  
SOURCE: Plasilova et al (7).  
Characteristic: TNBC n (%) P*
T stage:  
T1 
T2 
T3 
T4
46.4% 
38.1% 
8.4% 
7.1%
<0.001
N stage: 
N0 
N1 
N2 
N3
72% 
20.1% 
4.7% 
3.3%
<0.001
M stage: 
M0 
M1
94.1% 
5.9%
<0.001
Mean tumor size (cm±SE): 2.78±0.012 <0.001
Tumor grade 
I 
II 
III
2.4% 
17.8% 
79.8%
<0.0001
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 The overall outcome in TNBC is significantly worse than in the other subtypes, as 42.2% of 
the patients with TNBC died compared to 28%. TNBC has an especially higher mortality rate in the 
first five years following diagnosis with 70% of all TNBC-related deaths occurring during this time, 
but all deaths occur within ten years of diagnosis, while for the other subtypes the mortality rate 
continues for around 18 years (28). But as TNBC represents a heterogeneous group, not every 
single type has a poor prognosis, for example, adenoid cystic and secretory carcinoma, present with 
a rather indolent course and therefore have a better prognosis even without chemotherapy being 
used as the treatment option (30). Albeit as shown in Figure 6, the overall probability of survival in 
TNBC in continuously lower than in other BCs. TNBC is an exceptionally rapidly progressing 
cancer, with a survival time of only nine months from distant recurrence on, compared to 20 months 
in other breast cancers (28). 
 Last but not least, patients who are older than 70 years at the time of diagnosis have a 
superior prognosis compared to younger women with TNBC, and black ethnicities have generally 
as a whole an inferior prognosis (11,31). 
Figure 5. Distant recurrences after surgery in TNBC and other types of breast cancers.  
SOURCE: Dent et al (28). 
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Figure 6. Comparison of survival rates in TNBC and other breast cancers (28).  
SOURCE: Dent et al (28). 
1.2.5 Diagnostics 
 As TNBC is a very aggressive subtype and usually presents in advanced stages, it is crucial 
to know its main imaging features, especially as they often lack the typical suspicious features for 
malignancies, like an irregular shape, speculated margins and calcifications. On mammography, 
TNBC usually appears as an interval cancer, as in spite of its large size at the time of diagnosis, it is 
often occult on initial mammography scans (18%). Distinct characteristics of mammography for 
TNBC are in contrast to the ones for other breast cancer types, and thus it may be useful in the 
diagnosis and differentiation of TNBC, as TNBC usually presents as a well-circumscribed mass in 
37.2% of the cases and without calcification in around 49-100% of the cases (27,32,33,34). More 
precisely speaking, calcifications are absent in 83.3% of visible masses, and there is total lack of 
calcifications in 74.1% of scans, which are significantly higher percentages compared to non-
TNBCs. The shape is mostly round to oval (58.1%) and sometimes lobular (30.2%) (34).  
 Ultrasound (US) has a very high sensitivity for triple-negative breast cancers (92-100%), but 
caution as TNBC usually presents with prevalent signs of benign neoplasms, cysts, and abscesses, 
meaning as a distinct mass that has with well-circumscribed margins (21-27%) and shows posterior 
acoustic enhancement (24-41%), which can also be indicative for a tumor necrosis associated fluid 
component (27,32,34). 
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 Magnetic resonance imaging (MRI) is the most sensitive method to detect TNBC, with a 
visualization rate of 100%. The lesions appear with smooth margins, but also with rim 
enhancement, which is a highly predictive characteristic of malignancy. Furthermore, features are 
persistent enhancement patterns and, on T2-weighted images, a high intratumoral signal intensity 
(35). A study from 2007 with a rather small sample 29 patients states that at the time of diagnosis, in 
21% of the cases multifocality is visible, as well as in 34% prominent skin enhancement indicating 
dermal lymphatic invasion in tumors smaller than five centimeters. The mean tumor of this study is 
size 4.1 ± 2.7 cm and 79% of the cases presented at least at grade II (36,37). Dynamic MRI shows 
vascular differences between TNBC and the other subgroups, observing a significantly higher 
outflow rate and smaller leakage space in TNBCs (38). To sum up,  the TNBC visualization rates of 
the three main diagnostic methods, mammography, US, and MRI are very high, 91%, 93% and 
100% respectively (34). 
 Another imaging procedure, rather than a primary diagnostic method, that can be performed 
is [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (18F-FDG-PET), it is useful for 
detecting metastasis and to follow-up the response to chemotherapy (32,39).  
1.2.6 Classification of breast cancer 
 According to the WHO classification from 2012, there are for the time being 21 
morphologically distinct subtypes of invasive breast cancer (IBC), which make it a very 
heterogeneous group with distinct pathological and molecular characteristics. The whole list of all 
acknowledged breast cancers is added in the supplement section, Figure 2.  The most common IBC 
type is the invasive carcinoma of no special type, also known as invasive ductal carcinoma, which 
makes up between 40 to 75% in published series (40). Invasive ductal carcinoma comprises even a 
more significant percentage among TNBCs with a 90% majority of TNBCs being unifocal, invasive 
ductal carcinomas. All the other histological types of TNBC are classified as either medullary, 
secretory, adenoid cystic, apocrine, metaplastic, invasive lobular carcinoma, or microglandular 
adenosis carcinomas (27). 
 Up to this point, the morphological diagnosis and the contemporary staging systems are 
rather inadequate and disorganized; consequently, they are currently evolving into a multi-
classification system which integrates the morphological diagnosis of cancer, immunohistochemical 
assessment, DNA microarray analysis, and CIRCOS Plot to improve the therapy response rate and 
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overall outcomes (41). However, for the time being, the guidelines for breast cancer therapy focus 
on a combination of pathological classification, the histological grade of cancer, ER, PR, and HER2 
status (42). But, due to the advancement of molecular procedures, such as DNA microarray analysis 
which focuses on gene expression profiling, the concept of heterogeneity of breast cancer has 
become accepted and the importance in diagnosis shifted to ”Molecular Classification” of breast 
cancers — leading to the development of targeted therapeutics and individualized treatment (43).   
 Figure 7 shows eleven distinct histopathological pictures of eight different types of breast 
cancers stained with hematoxylin and eosin (H&E). The different classes show slight differences, 
but the cancer cells are highly coherent. Histopathological slides show significant variations making 
differentiation of breast cancer types hard (44).  
 
Figure 7.  Histopathological images of the eight most common breast cancer types at a 
magnification factor of 400.  
SOURCE: Han et al (44). 
 The importance of immunohistochemistry is presented in Figure 8, which shows the 
differences in H&E staining and immunohistochemical patterns for various breast cancer types, 
with a focus on TNBC divided by its basal-like subtype and non-classified TNBCs. Most commonly 
ER, PR, and HER2 are used in IHC, which divides IBC into TNBC, luminal, and HER2 breast 
cancer subtypes. With further IMC surrogates, more subdivisions can be made, like for example 
Ki-67, cytokeratin 5, and EGFR separating the basal-like breast cancer subtype from TNBC, and 
luminal breast cancers in A and B subtypes (42).  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Figure 8. Histological images with hematoxylin-eosin stain (H&E) and immunohistochemical 
patterns for seven molecular breast cancer subtypes.  
Abbreviations: BC, breast cancer; BLBC, basal-like subtype; CK5, high–molecular weight 
cytokeratin expressed in normal myoepithelial cells; EGFR, epidermal growth factor receptor; ER, 
estrogen receptor; HER2, human epidermal growth factor receptor-2; NCBC, nonclassified subtype; 
PR, progesterone receptor; TNBC, triple-negative breast cancer.  
SOURCE: Tang et al (42). 
 Subclassifying the TN phenotype is somewhat tricky, considering that the only unifying 
feature being the lack of three biomarkers. Figure 9 emphasizes this heterogeneity by showing 
various histopathological TNBC subtypes and their degree of low- to high-grade cancers. Although 
progression to high-grade cancers is typical in TNBC it is with varying rates depending on the 
histological type, i.e., prevalent in acidic cell carcinoma and rare in salivary gland-like breast 
tumors, resulting in some subgroups having a low histologic grade and rather indolent behavior, 
even though in general TNBC is known for its aggressive presentation (45). For example, adenoid 
cystic and secretory carcinomas of the breast, are TNBCs with an indolent course and especially a 
better prognosis even without chemotherapy (29). 
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Figure 9. Spectrum of low to high-grade TNBCs.Various histopathological subtypes of TNBC are 
connected to their known specific genetic alterations. Progression from low to high-grade TNBC is 
common but occurs at different rates. *Evidence for polymorphous carcinoma of the breast 
mutation PRKD1 E710D or PRKD1/2/3 rearrangements still needs to be documented. 
Magnification factor of 200.  
Abbreviations: PI3K, phosphatidylinositol 3-kinase.; TNBC, triple-negative breast cancer.  
SOURCE: Geyer et al (45). 
1.2.7 Therapeutic options and advances 
 Due to the fact that there are no proper standard treatment regimens or even options 
available for TNBC, there are various therapeutic approaches, ranging from local therapy, meaning 
surgery and radiation to systemic approaches involving chemotherapy, targeted therapies, 
immunotherapeutic approaches, to the option of breast cancer vaccines, but most potentially more 
potent therapeutics are still under investigation so far in clinical or like our compound in preclinical 
trials (27).  
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 Local therapy for TNBC is applied in a comparable way as to other IBCs and involves 
removal of the cancerous lump by either breast-conserving surgery (BCS) or mastectomy supported 
by radiotherapy (RT), as there are no TNBC-specific local therapy recommendations. The breast-
conserving procedure remains the standard therapy for small T1 and T2 BCs, and mastectomy is for 
more extensive, multifocal cancers, or in patients with positive margins after BCS (8,27). A study 
from 2017 highlights the point that there is insufficient data, to imply that mastectomy is better than 
BCS, but also points out that systemic recurrence remains higher in TNBC patients emphasizing the 
importance of more efficient systemic therapeutic options (46). There are no distinguished 
guidelines for adjuvant RT in TNBC, and the better outcome in BCS is determined by the fact that 
three-year relapse-free survival is 79.6% in patients treated with RT compared to 57.9% in patients 
without RT, even though the patients with RT had a higher cancer stage (27).  
 Since appropriate targets in TNBC for systemic approaches are missing, chemotherapy 
remains the primary treatment for TNBC, with no difference in the outcome whether or not the 
therapy is started pre- or postoperative in early-stage TNBCs, but several other systemic treatment 
options are momentarily under investigation (27,47). Even though the response to chemotherapy in 
TNBC is superior compared to other BC types, the five-year survival is by less than 30% of women 
with metastatic disease (48). So far anthracycline-taxane-based chemotherapy remains the standard 
neoadjuvant systemic treatment (NST), but the addition of platinum-based agents in NST is 
considered, in defiance of the added toxicity several papers say that it shows better clinical response 
to systemic therapy and could possibly improve local therapy, however some state that it does not 
improve survival (47,48). 
 Many promising therapies are under investigations to allow personalized treatment strategies 
in this heterogeneous disease, like immunotherapeutic approaches and the oncolytic vaccinia virus, 
which does not only show promising results in preventing metastasis but also in treating it (27). 
Another approach is targeted therapies concentrating on, for example, PARP inhibitors, anti-
androgen therapy, PI3K inhibitors, MEK inhibitors, and inhibitors of cancer stem cells. This study 
focuses on a novel therapeutic compound to counter the BCSC population, which is known to be 
more resistant to chemotherapy than cancers without stem cells (48).  
"18
2. OBJECTIVES AND HYPOTHESES 
2.1 Objectives 
 The aim of this study is to determine the effects of treating breast cancer stem cells with the 
newly synthesized thieno[2,3-b]pyridine anticancer agent, by focusing on its cytotoxic and 
apoptotic effects on the investigated human cell line MDA-MB-231. 
2.2 Hypotheses 
1. Treating the MDA-MB-231 cell line with compound 1 will have a cytotoxic effect on the breast 
cancer stem cells. 
2. Compound 1 will lead to an increased apoptotic rate in the MDA-MB-231 breast cancer stem 
cell line. 
3. The percentage of the breast cancer stem cell subpopulation will be decreased following the 
treatment with compound 1. 
4. The effects of compound 1 will be in a dose- and time-dependent manner.  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3. MATERIALS AND METHODS  
3.1 Chemistry and cell line 
 3-Amino-N-(3-chloro-2-methylphenyl)-5-oxo-5,6,7,8-tetrahydrothieno[2,3-b]quinoline-2-
carboxamide (compound 1) (Figure 10) was dissolved in dimethyl sulfoxide (DMSO). Cells were 
purchased from the American Type Culture Collection (ATCC, LGC Standards), the cell 
micrograph is shown in Figure 11. The MDA-MB-231 breast cancer stem cells were grown in a 
Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma-Aldrich, Steinheim, Germany) with 10% 
fetal bovine serum (FBS, EuroClone) supplemented with 1% antibiotics (Penicillin-Streptomycin, 
EuroClone). The culture conditions were in a humidified incubator at 37°C with an atmosphere of 
5% CO2. The known characteristics of the cell line are presented in the table below (Table 4). 
 
Figure 10. The structure of the newly synthesized anticancer agent (compound 1).  
Note: Compound 1, 3-Amino-N-(3-chloro-2-methylphenyl)-5-oxo-5,6,7,8-tetrahydrothieno[2,3-
b]quinoline-2-carboxamide.  
 
Figure 11. Cell micrograph  
SOURCE: https://www.lgcstandards-atcc.org (49).  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Table 4. Characteristics of MDA-MB-231 cell lines 
SOURCE: https://www.lgcstandards-atcc.org (49).  
Characteristics:
Organism: Homo sapiens, human
Tissue: mammary gland/breast; derived from metastatic site: pleural effusion
Disease: adenocarcinoma
Cell Type: epithelial
Age: 51 years adult
Gender: female
Ethnicity: Caucasian
Morphology: epithelial
Culture Properties: adherent
Biosafety Level: 1 
Biosafety classification is based on  
U.S. Public Health Service Guidelines
Product Format: frozen
Applications: these cells are a suitable transfection host
Storage Conditions: liquid nitrogen vapor phase
Receptor Expression: epidermal growth factor (EGF), expressed 
transforming growth factor alpha (TGF alpha), expressed
Oncogene: the cells express the WNT7B oncogene
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3.2 Colorimetric MTT assay 
 A tetrazolium-based colorimetric MTT assay was performed, to analyze the cell viability 
and in doing so determining the cytotoxic effect of the novel anticancer compound on triple-
negative breast cancer stem cells. The cell proliferation was measured by first diluting the cells in a 
solution of trypan blue and Neubauer chambers counted by MOTIC AE30, an inverted binocular 
microscope. The cell number was calculated according to the formula: number of counted cells x 10 
× 104/mL. A homogenous number of cells were then seeded in 96-well plates at a density of 104 
cells/100 µL and incubated during the night to allow attachment (Figure 12). The cells were treated 
in a complete medium and the experiments performed in triplicate, for 4, 24, 48 and 72 h with 
specific solutions of compound 1 at a concentration of 50 nM, 250 nM, 500 nM, 1 µM and 5 µM. 
Thereupon, the MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] assay was 
performed, and the treated cells were incubated with 0.5 g MTT/L at 37°C for 1 hour, the medium 
was removed and in the end dimethylsulphoxide (10% DMSO) was added and incubated for 
another 10 minutes at 37°C with shaking. Absorbance was measured photometrically at a signal 
wavelength of 570 nm and depends on the degree of formazan formation (Figure 13), which 
indicates cell viability and their metabolic activity. The collected data was calculated in comparison 
to the untreated control (100%) from three independent measurements. 
Figure 12. MDA-MB-231 in 96-well plates and treated with compound 1.  
SOURCE: Biochemistry Laboratory, Medical Faculty of Split. 
"24
Figure 13. Enzymatic formazan formation in MTT.  
SOURCE: Kuete et al (50). 
3.3 Flow cytometric analysis 
 A homogenous number of cells were plated onto six-well plates at a density of 104 cells/100 
µL and treated with 2 µM compound 1 for 48 h and afterward analyzed for apoptosis. The combined 
staining of propidium iodide and Annexin-V-FITC makes it possible to properly distinguish 
between early (Annexin-V+/PI-) and late (Annexin-V+/PI-) apoptotic cells, necrotic cells, and live 
cells. Following the treatment with compound 1 the cells were trypsinized, then washed with 
phosphate-buffered saline (PBS) and at last resuspended in 100 µl of the binding buffer containing 
5 µl of propidium iodide and/or 5 µl Annexin-V-FITC (Annexin-V-FITC Apoptosis Detection Kit I, 
BD Biosciences, San Jose, CA, USA). Then, the cells were incubated in the dark at room 
temperature for 15 minutes and after that flow cytometric analysis was carried out (BD Accuri C6, 
BD Biosciences). Using the FlowLogic Software (Inivai), the degree of apoptosis (Annexin-V 
positive cells) was analyzed and presented as mean ± SD. 
 Besides, to detect the percentage of CD44+/CD24- cells, the cells administered with 
compound 1 and the controls were trypsinized and washed with PBS. Furthermore, the cells were 
prepared with an Fc receptor-blocking reagent (Miltenyi Biotec GmbH, Bergisch Gladbach, 
Germany) to avoid the occurrence of nonspecific binding from happening. Following another 
incubation at room temperature for 15 minutes with diluted anti-CD15s (BD Biosciences), the cells 
were additionally diluted with anti-CD44-FITC (BD Biosciences), anti-CD24-PE (eBioscience, 
Inc., San Diego, CA, USA) and secondary antibody conjugated with eFluor 660 fluorochrome 
(eBioscience, Inc.) and anew incubated for 15 minutes in the dark. Eventually, the cells were 
resuspended in PBS and then analyzed by flow cytometry (BD Accuri C6; BD Biosciences).  
"25
3.4 Statistical analysis 
 The results were statistically analyzed using the statistical software Statistica issued for 
Windows version 7.0 (Stat Soft, Tulsa, OK, USA), where P<0.05 indicates a statistically significant 
difference. 
 The colorimetric MTT assay results were statistically analyzed by a one-way ANOVA 
followed by post-hoc Tukey test (MTT results after 4, 48, and 72 hours) or post-hoc Dunn test 
(MTT results after 24 hours). Data represent the percentage of live cells and mean ± SD. 
 From the flow cytometric analysis the results are presented as mean ± SD of Annexin-V+/PI- 
cells and CD44+/CD24- cells. Percentage of early apoptosis, as well as the percentage of CD44+/
CD24- cells is determined using a two-tailed paired t test. 
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4. RESULTS  
4.1 Compound I: dose- and time-dependent cytotoxicity 
 In this study, we analyzed cell viability by MTT assay after 4, 24, 48, and 72 hours treated 
with compound 1 is shown in Figure 10. Cytotoxic effect of compound 1 is already observable after 
4 hours of treatment with a concentration of 0.5 µM. Even ten times lower concentrations (50 nM) 
are effective after a prolonged period of 48 hours. Maximal cytotoxicity was obtained after 72 hours 
treatment with 5 µM compound 1, for merely 47% of cells. 
 
Figure 14. Cell viability after drug treatment.  
Notes: Compound 1 produces a dose- and time-dependent metabolic defect in MDA-MB-231 cell 
line. Cells were treated with a dose-dependent curve of 1 as shown in the Figure for 4, 24, 48 and 
72 h and cell metabolism evaluated by the MTT assay. Data represent the mean from experiment 
performed in triplicate ± SD. Columns, mean of viable cells; bars, SD; *P<0.05; **P<0.01; 
***P<0.001. 
Abbreviations: SD, standard deviation; SP, control. 
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4.2 Compound I: cell death of breast cancer stem cells 
 To determine the cause of the MTT findings, we subsequently determined the type of cell 
death induced by 48-h treatment with 2µM compound 1. Compound 1 shows a prominent increase 
in early apoptosis in MDA-MB-231 cells compared to non-treated cells, as the percentage of early 
apoptosis in treated cells is around 9% and in untreated cells less than 2%. Therefore we can 
conclude that cell death mainly occurs due to treatment-induced apoptosis (Figure 15). 
 
Figure 15. Apoptosis after drug treatment.  
Notes: Apoptosis after treatment with 2µM compound 1 (inhibitor) for 48 h in MDA-MB-231. Data 
represent the mean ± SD of Annexin-V+/PI- cells. Percentage of early apoptosis is given in bar 
charts for treatment compared to the control. Columns, mean of cells; bars, SD; *P<0.05.  
Abbreviations: SD, standard deviation. 
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4.3 Compound I: decrease in number of BCSC 
 In the TNBC cell line MDA-MB-231, the marker combination CD44+/CD24- is known to be 
numerously common in CSC as mentioned before. The treatment with compound 1 shows a 
statistically significant decrease of the CD44+/CD24- subpopulation, with 89,86% in untreated 
control and 55.54% after treatment with 2µM compound 1 for 48 hours (t=8.324 df=5 P <0.001). 
 
Figure 16. CSCs (CD44+/CD24-) after drug treatment.  
Notes: Percentage of CSCs after treatment with 2µM compound 1 for 48 h in MDA-MB-231. Data 
represent the mean ± SD. Percentage of CSC is given in bar charts for treatment compared to the 
control. Columns, mean of cells; bars, SD; *P<0.001.  
Abbreviations: CSCs, cancer stem cells; SD, standard deviation. 
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5. DISCUSSION 
 Acknowledging that targeting CSC is an auspicious strategy to defeat tumor recurrence and 
immunity to chemotherapy, the focus of this study was to determine, whether the newly synthesized 
putative phospholipase C (PLC) inhibitor, 3-amino-N-(3-chloro-2-methylphenyl)-5-oxo-5,6,7,8-
tetrahydrothieno[2,3-b]quinoline-2-carboxamide (compound 1; Figure 10), has cytotoxic properties 
and is able to induce cell death and therefore a potentially new therapeutic approach to treat TNBC 
(51). As it is ascertained that thieno[2,3-b]pyridine works against the phospholipase C-γ2 (PLC-γ2) 
isoform, a novel therapeutic target for molecular anticancer treatments which is an efficient 
anticancer agent against various cancer cell lines, we wanted to determine its potency against 
TNBC (52). 
 Performing a colorimetric MTT assay to analyze the cell viability of TNBC cells treated 
with different concentrations for various time intervals, we found that the newly synthesized 
anticancer compound shows a dose- and time-dependent cytotoxicity for breast MDA-MB-231 
cancer cells. The novel compound under investigation is already cytotoxic at the lowest 
concentration tested after a prolonged period of 48 hours of treatment compared to the ten times 
higher concentration which is already cytotoxic after only four hours, the maximal cytotoxicity was 
achieved after treatment with maximal concentration at the longest time interval, but only for 47% 
of cells (Figure 14). This shows how increasing the dose and time raises the cytotoxic effect of 
compound 1 on MDA-MB-231. The performance of this experiment was done in triplicate to 
exclude any errors., however, the MTT assay used in our investigation, does not take into account 
whether the viable cells measured undergo active cell division or not. This means, we cannot 
exclude cytostatic qualities of the novel compound, that it for example, induces G2/M phase cell 
cycle arrest, and measured discrepancy is probably due to different analytical methods. 
 To determine the type of cell death, flow cytometric analysis was performed and we tested 
the compound at a concentration of 2 µM after 48 hours. The results show a significant increase in 
early apoptosis in MDA-MB-231 cancer cells in comparison to non-treated cells, meaning that the 
majority of cells died by treatment-induced apoptosis (Figure 15). The same test was used to find 
out whether or not the percentage of BCSC is also declining, showing a prominent decrease in the 
CD44+/CD24- subpopulation, which represent the tumorigenic stem cell-like properties. The high 
level of treatment-induced apoptosis and the significantly lowered BCSC subpopulation is so 
relevant because SCs are responsible for extensive self-renewal, proliferation, quick cancer 
progression, as well as metastasis disease in cancer patients, and up to this point no satisfying 
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therapy exists for TNBC, so it seems promising for treating TNBC, especially the metastatic form 
(19,20). However, in the context of this diploma thesis, we did not take into account the 
glycosphingolipid expression on the surface of CSCs which are responsible for cancer relapse and 
therapy resistance in TNBC, so we cannot say which receptors are associated and working together 
with the new compound and mediating the treatment-induced apoptosis and therefore also lowering 
the percentage of BCSCs (53).  
 In a similar study, another compound from the thieno[2,3-b]pyridine class was also used on 
the MDA-MB-231 cell line, showing comparable results. For the MTT assay the same time 
intervals were used but coupled with higher concentrations,  0.5 µM, 1 µM, 5 µM, 10 µM, and 25 
µM of the thieno[2,3-b]pyridine compound. Anyways, it was also noticed that the compound 
produces a dose- and time-dependent cytotoxicity with regular growth retardation for MDA-
MB-231 cells. Furthermore, it was also investigated whether the MTT results are caused by cell 
death or cell cycle arrest. Determination of the type of cell death was done by flow cytometric 
analysis with the same standards that were used in this study and it shows that compound-induced 
cell death occurs also mostly by early apoptosis, but it destroys a higher percentage than the 
compound tested in this study. Moreover, the decrease in BCSC was also observed but was not as 
prominent as in this study. However, they were also able to associate increased levels of GM3 
expression on MDA-MB-231 cells to a higher apoptotic rate and a lower percentage of BCSC 
subpopulation. 
 Limiting factors to the study must be considered when interpreting and applying the 
conclusion. However, no major limitations to this study are established as every experiment was 
performed in triplicate. Albeit, one could test this novel compound on another TNBC cell line to 
confirm its therapeutic effects and compare the results to this study, allowing better comparison of 
the cytotoxic strength of this compound on TNBC stem cells. 
 This study conclusively confirms that the novel thieno[2,3-b]pyridine compound has a 
cytotoxic effect on the MDA-MB-231 TNBC stem cell line in not only a time- but also a dose-
dependent manner. The most significant results obtained by this research concluded that the 
treatment-induced cell death is mainly due to an increased apoptotic rate. Furthermore, compound 1 
considerably decreases the CSC subpopulation percentage found in TNBC. 
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 Taking into account that several studies working with compounds of the thieno[2,3-
b]pyridine class described efficient anticancer qualities against several types of cancers, these 
compounds targeting PLC-γ2 should be paid more attention to, especially for TNBC which has no 
sufficient therapeutic regime yet (52,53). However, so far only in vitro trials on cancer cell lines 
were done and for the future the compounds have to be tested for whether or not they are only 
cytotoxic for cancerous cells or also for healthy tissue, to exclude any unwanted side effects. 
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6. CONCLUSIONS 
• According to the results we obtained in this study, we were able to demonstrate that the treatment 
of human MDA-MB-231 TNBC with compound 1 works and has cytotoxic effects on the 
investigated cell line.  
• The results show that compound 1 leads to a higher level of apoptosis and a significantly lowered 
percentage of the CSC subpopulation. 
• Furthermore, to be more precise the results concluded that compound 1 affects TNBC in a dose- 
and time-dependent cytotoxic manner. 
• This study conclusively shows that if one considers the fact that TNBC’s characteristic property 
is an increased percentage of BCSCs and knowing its connection to being at a higher risk for 
metastatic disease and mortality, the thieno[2,3-b]pyridine class of compound 1 definitely 
deserves further attention as a potentially new therapeutic approach for treating TNBC.  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8. SUMMARY  
Objectives: The purpose of this study is to determine the effects of treating breast cancer stem cells 
with the newly synthesized thieno[2,3-b]pyridine anticancer agent, by focusing on its cytotoxic and 
apoptotic effects on the investigated human cell line MDA-MB-231. 
Methods:  The MDA-MB-231 triple-negative breast cancer cell line was treated with a newly 
developed thienopyridine anticancer compound (3-amino-N-(3-chloro-2-methylphenyl)-5-
oxo-5,6,7,8-tetrahydrothieno[2,3-b]quinoline-2-carboxamide, 1) to determine its cytotoxic effect on 
triple negative breast cancer, the type of cell death it causes, and the cancer stem cell percentage 
after treatment. The 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) assay was 
performed, to analyze the cellular metabolic activity and determine the cytotoxic effect. Flow 
cytometric analysis was used in combination with Annexin-V-FITC and propidium iodide staining 
to assess the type of cell death after 48h of treatment with compound 1 (2 µM). Furthermore, flow 
cytometry also provided the percentage of CD44+/CD24-  cancer stem cells after treatment.
Results: Compound 1 was cytotoxic for breast cancer cells in a dose- and time-dependent manner; 
cell death occurs mainly by apoptosis. The percent of cancer stem cells decreased four times. 
Conclusion: Due to its cytotoxic effect on the percentage of triple negative breast cancer stem cells 
compound 1 can be a potential treatment for triple-negative breast cancer.  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9. CROATIAN SUMMARY  
Citotoksični učinak i apoptoza matičnih stanica karcinoma dojke tretiranih 
novosintetiziranim protutumorskim spojem tieno [2,3-b] piridinom 
Ciljevi: Cilj ovog istraživanja je utvrditi učinke tretmana matičnih stanica karcinoma dojke 
novosintetiziranim protutumorskim spojem tieno [2,3-b] piridinom, s naglaskom na njegove 
citotoksične i apoptotske učinke na ispitivanu staničnu liniju MDA-MB-231. 
Materijali i metode: Trostruko negativna stanična linija karcinoma dojke MDA-MB-231  tretirana 
je novosintetiziranim tieno-piridinskim spojem (3-amino-N-(3-kloro-2-metilfenil)-5- okso-5,6,7,8-
tetrahidrotieno[2,3-b]kinolin-2-karboksamid, 1) kako bi se utvrdio citotoksični učinak, tip stanične 
smrti i postotak matičnih stanica karcinoma nakon tretmana. Napravljen je MTT (3-(4,5-
dimetiltiazolil-2)-2,5-difeniltetrazolij bromid) test kako bi se analizirala stanična metabolička 
aktivnost i utvrdio citotoksični učinak. Protočna citometrija u kombinaciji s bojanjem aneksin-V-
FITC-om i propidij jodidom, korištena je kako bi se utvrdio tip stanične smrti nakon 48h tretmana 
spojem 1 (2 µM). Nadalje, protočnom citometrijom je također utvrđen postotak CD44+/CD24- 
matičnih stanica karcinoma nakon tretmana. 
Rezultati: Spoj 1 bio je citotoksičan za stanice karcinoma dojke te citotoksičnost korelira s 
koncentracijom spoja i vremenom inkubacije. Stanična smrt je nastupila prvenstveno zbog 
apoptoze. Postotak matičnih stanica karcinoma smanjio se četiri puta. 
Zaključci: Zbog citotoksičnog učinka na postotak matičnih stanica trostruko negativnog karcinoma 
dojke, spoj 1 može biti potencijalna terapija za trostruko negativni karcinom dojke.  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11. SUPPLEMENT  
Figure 1. 1.2.2 Epidemiology and etiology. World maps illustrating the most common type of 
cancer (A) incidence and (B) mortality by country in 2018 among females.  
SOURCE: Globocan 2018, World Health Organization (6). 
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A
B
Table 1. Frequency of PVs in African-American and Caucasian American.
Notes: 1.2.2 Epidemiology and etiology. Blue highlights the highest percentage of PVs found in 
both groups, red stands for mutations exclusively found in African-Americans, and green stands for 
PVs found only in Caucasian-Americans. 
Abbreviations: PV, pathologic variant; AA, African-American; CA, Caucasian-American.
SOURCE: Chang et al (11).
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Table 2. Specific characteristic differences for TNBC compared to other types of breast cancers. 
Notes: 1.2.4 Clinical features and prognostics. TNBC compared to nonTNBC  except the rows with 
odds ratios, where the P value represents TNBC compared to the reference, HR+ Her2.  
Abbreviations: TNBC, triple-negative breast cancer; CI, confidence interval; HR, hormone 
receptor; Her2, human epidermal growth factor receptor; OR, odds ratio; SE,standard error.  
SOURCE: Plasilova et al (7).  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Table 3. Differences between TNBC and non-TNBC on mammography. 
*P values were calculated using x2 test or the Student’s t-distribution.  
Notes: 1.2.5 Diagnostics.  
SOURCE: Gao et al (33). 
Characteristic: TNBC 
N=54 (%)
Non-TNBC  
N=5372 (%) P*
Mass: 
Yes 
No
34 (63.0)  
20 (37.0)
132 (35.5) 
240 (64.5)
<0.0001
Mass + calcifications:  
Yes 
No
9 (16.7)  
45 (83.3)
158 (42.5) 
214 (57.5)
<0.0001
Total mass: 
Yes 
No
43 (79.6) 
11 (20.4)
290 (78.0) 
82 (22.0)
0.7810
Total calcification:  
Yes 
No
14 (25.9) 
40 (74.1)
204 (54.8) 
168 (45.2)
<0.0001
Mass shape: 
Round/oval 
Lobular  
Irregular
N=43 
25 (58.1) 
13 (30.2) 
5 (11.6)
N=290 
64 (22.1) 
91 (31.4) 
135 (46.6)
<0.0001
Mass margins: 
Circumscribed  
Obscured  
Microlobulated  
Indistinct 
Spiculated
N=43 
16 (37.2) 
7 (16.3) 
11 (25.6) 
5 (11.6) 
4 (9.4)
N=290 
10 (3.4) 
18 (6.2) 
87 (30.0) 
80 (27.6) 
95 (32.8)
<0.0001
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Figure 2. WHO Classification of tumours of the breast.
Notes: 1.2.6 Classification of breast cancer.  
SOURCE: Makhani et al (40)  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Table 4. MTT results. 
Notes: 4.1 Compound I: dose- and time-dependent cytotoxicity.
SP 50 nM 250 nM 500 nM 1 µM 5 µM
After 4 hours 0,132 0,135 0,133 0,106 0,109 0,102
0,144 0,128 0,12 0,08 0,115 0,083
0,126 0,135 0,088 0,078 0,113 0,077
0,132 0,12 0,101 0,102 0,124 0,052
0,154 0,108 0,128 0,12 0,123 0,049
Average 0,1376 0,1252 0,114 0,0972 0,1168 0,0726
Mean 1 0,909883 0,828488 0,706395 0,848837 0,527616
SD 0,081835 0,083084 0,137794 0,130247 0,047210 0,161412
After 24 hours 0,152 0,079 0,116 0,083 0,107 0,108
0,139 0,089 0,126 0,124 0,074 0,128
0,131 0,145 0,126 0,109 0,119 0,112
0,131 0,148 0,142 0,118 0,107 0,111
0,122 0,138 0,137 0,111 0,118 0,095
Average 0,135 0,1198 0,1294 0,109 0,105 0,1108
Mean 1 0,887407 0,958518 0,807407 0,777777 0,820740
SD 0,083312 0,244971 0,075831 0,116298 0,135273 0,087237
After 48 hours 0,267 0,209 0,198 0,19 0,17 0,142
0,287 0,212 0,195 0,165 0,158 0,139
0,274 0,187 0,198 0,175 0,177 0,149
0,287 0,2013 0,209 0,172 0,184 0,141
0,29 0,226 0,208 0,178 0,169 0,12
Average 0,281 0,1198 0,2016 0,176 0,1716 0,1382
Mean 1 0,736868 0,717437 0,626334 0,610676 0,491814
SD 0,035498 0,051029 0,022870 0,032713 0,034558 0,038608
After 72 hours 0,232 0,187 0,139 0,149 0,144 0,114
0,225 0,161 0,138 0,133 0,141 0,12
0,221 0,157 0,158 0,15 0,13 0,115
0,216 0,167 0,156 0,162 0,135 0,132
0,237 0,169 0,153 0,152 0,146 0,131
0,242 0,15 0,154 0,146 0,158 0,122
Average 0,228833 0,165166 0,149666 0,148666 0,142333 0,122333
Mean 1 0,721777 0,654042 0,649672 0,621995 0,534595
SD 0,043297 0,055580 0,038561 0,041149 0,042338 0,033699
"55
